Recombinant human p53 adenovirus injection (rAd-p53) combined with chemotherapy for 4 cases of high-grade serous ovarian cancer.

Recombinant human p53 adenovirus injection (rAd-p53) combined with chemotherapy for 4 cases of high-grade serous ovarian cancer. Curr Gene Ther. 2020 Aug 25;: Authors: Qu H, Xia Y, Li X Abstract High-grade serous ovarian carcinoma (HGSOC) is one of the most common ovarian epithelial carcinomas. It is highly invasive, easily recurs after systemic treatment, and has a poor prognosis. Despite many new chemotherapeutic drugs and trials of combinations of different regimens that have been used in treatment attempts, there has been no meaningful progress in the treatment of HGSOC. With the development of gene sequencing technology, gene therapy has become a new direction for tumors treatment. It's reported that the P53 has a very high mutation rate in HGSOC, which provides a theoretical basis for the application of gene therapy in HGSOC patients. Recombinant human p53 adenovirus injection (rAd-p53) is the world's first approved oncology gene therapy drug. In this article, we retrospectively analyzed 4 cases of HGSOC patients treated with rAd-p53. Three of them were recurrent ovarian cancer, and one was initial treatment. The treatment method was to apply recombinant human p53 adenovirus injection (rAd-p53) to the lesions for local injection, 72 hours later, the lesions were injected with bleomycin or fluorouracil, and systemic intravenous chemotherapy was performed simultaneously. After rAd-p53 treatment, one of the three relapsed ovarian ...
Source: Current Gene Therapy - Category: Genetics & Stem Cells Authors: Tags: Curr Gene Ther Source Type: research